Abstract:Objective For major depressive disorder (MDD), there has been a lack of neuroimaging markers of efficacy of pharmacological treatment. In this study, we aimed to explore the neuroimaging mechanisms in patients with first-episode MDD and identify markers that predict the efficacy of 5-hydroxytryptamine reuptake inhibitors (SSRIs) with the use of resting-state brain imaging technology. Methods A total of 101 patients with first-episode MDD and 53 normal controls were finally included in this study. Based on the reduction rate of the score of Hamilton Depression Rating Scale (HAMD-17) during the 2-week SSRI treatment, 31 patients were assigned into the unresponsive group and 32 were assigned into the responsive group. The brain function was compared between patients with MDD and normal controls, and the diagnostic value of brain function was analyzed. With brain regions showing differences between patients with MDD and normal controls as a mask, and the brain function between the responsive and unresponsive groups were compared. Correlations between brain function the HAMD-17 score reduction rate during the 2-week SSRI treatment were analyzed. Results Compared to normal controls, patients with MDD showed increased ReHo in the left parahippocampal gyrus and right parahippocampal gyrus, decreased ReHo in the right middle occipital gyrus, and decreased functional connectivity between the right and left parahippocampal gyri, right middle occipital gyrus and middle temporal gyrus. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) was 0.544 (95% CI: 0.445–0.644) for ReHo and 0.822 (95% CI: 0.734–0.909) for functional connectivity. Logistic regression pooling of the differences in ReHo mean time series with the functional connectivity mean time series was performed for the ROC curve analysis, which showed an AUC of 0.832 (95% CI: 0.752–0.911). Compared to the responsive group, the unresponsive group showed elevated ReHo in the right parahippocampal gyrus and lower functional connectivity in the middle temporal gyrus. We also found that the ReHo value was negatively correlated with the HAMD-17 score reduction after 2 weeks of SSRI treatment. Conclusion Altered resting-state brain function in some regions might be a neurobiological marker for the diagnosis of MDD, and ReHo values are expected to be predictors of patient response to treatment with SSRIs. Clinical Trial Registration [ http://www.chictr.org.cn/ ], identifier [ChiCTR1900028722].

Towards a neuroimaging biomarker for predicting cognitive behavioural therapy outcomes in treatment-naive depression: preliminary findings

Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial

Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study

Sub-hubs of Baseline Functional Brain Networks Are Related to Early Improvement Following Two-Week Pharmacological Therapy for Major Depressive Disorder.

Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia

A multivariate neuroimaging biomarker of individual outcome to transcranial magnetic stimulation in depression

Distinct Features of Cerebral Blood Flow and Spontaneous Neural Activity as Integrated Predictors of Early Response to Antidepressants.

Regional homogeneity in first-episode patients with mild-to-moderate depressive disorder before and after cognitive-behavior therapy:a resting-state fMRI study

Use of Machine Learning in Predicting the Efficacy of Repetitive Transcranial Magnetic Stimulation on Treating Depression Based on Functional and Structural Thalamo-Prefrontal Connectivity: A Pilot Study.

Identifying neuroimaging biomarkers of major depressive disorder from cortical hemodynamic responses using machine learning approaches

Multiband EEG signature decoded using machine learning for predicting rTMS treatment response in major depression

Changed Resting-State Brain Signal in Parkinson's Patients With Mild Depression.

Predicting Responses to Electroconvulsive Therapy in Adolescents with Treatment-Refractory Depression Based on Resting-State fMRI

Predict Value of Functional Topological Features for Early Response to Antidepressant Treatment in Major Depressive Disorder

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Combination of Spontaneous Regional Brain Activity and HTR1A/1B DNA Methylation to Predict Early Responses to Antidepressant Treatments in MDD

Baseline Clinical and Neuroimaging Biomarkers of Treatment Response to High-Frequency rTMS Over the Left DLPFC for Resistant Depression

Can we predict who will benefit from cognitive-behavioural therapy? A systematic review and meta-analysis of machine learning studies

Deviant spontaneous neural activity as a potential early-response predictor for therapeutic interventions in patients with schizophrenia

Prediction of Early Antidepressant Efficacy in Patients with Major Depressive Disorder Based on Multidimensional Features of Rs-Fmri and P11 Gene DNA Methylation